drugset

drugset / Trial / NCT00922441

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

NCT00922441 ↗

Phase 2 Completed 92 enrolled Boryung Pharmaceutical Co., Ltd Catholic Medical Center · collab Chonnam National University Hospital · collab Inje University · collab Kyungpook National University Hospital · collab Seoul National University Hospital · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.

Timeline

Start: 2008-12
Primary completion: 2009-08
Completion: 2009-08

Publications

Lee H, Kim KS, Chae SC, Jeong MH, Kim DS, Oh BH. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension. Clin Ther. 2013 Sep;35(9):1337-49. doi: 10.1016/j.clinthera.2013.06.021. Epub 2013 Aug 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fimasartan	Small molecule	60 mg	Oral
Subject	Fimasartan	Small molecule	120 mg	Oral
Comparator	Valsartan	Small molecule	80 mg	Oral

Indications